<DOC>
	<DOCNO>NCT01967095</DOCNO>
	<brief_summary>The purpose study test safety different way take erlotinib . The investigator want find effect , good and/or bad , combination daily low dose twice weekly high dose erlotinib patient lung cancer . The investigator also see whether different schedule erlotinib good treat lung cancer spread central nervous system . CNS expansion phase : The pulse continuous regimen assess patient EGFR mutant lung cancer CNS involvement . An additional expansion cohort ( A ) enroll 19 patient newly diagnose EGFR mutant lung cancer CNS involvement diagnosis . The patient expansion cohort undergo treatment plan patient dose expansion cohort . A patient expansion cohort replace he/she finish first 28 day ( cycle 1 ) treatment period .</brief_summary>
	<brief_title>Low Dose Daily Erlotinib Combination With High Dose Twice Weekly Erlotinib Patients With EGFR-Mutant Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>MSKCC pathologicallyproven diagnosis locally advanced Stage III amenable definitive , curative treatment Stage IV recurrent nonsmall cell lung cancer Documented presence EGFR mutation confirm MSKCC local facility . No prior treatment erlotinib , gefitinib , EGFR tyrosine kinase inhibitor Age ≥ 18 year Measurable ( RECIST 1.1 ) indicator lesion previously irradiate . Karnofsky Performance Status ≥ 70 % Ability take oral medication A negative serum pregnancy test obtain within 4 week prior start treatment woman childbearing potential . All woman child bear potential sexually active men must agree use adequate method birth control throughout study include use oral contraceptive additional barrier method , double barrier method , DepoProvera , permanent sterilization patient partner total abstinence . Expansion A : brain metastasis leptomeningeal previously treat radiation surgery Inadequate recovery toxicity relate prior treatment ( Grade 2 baseline ) . Inadequate hematologic function define ANC &lt; 1000 cells/mm³ , Platelet count &lt; 75,000/mm³ Hemoglobin &lt; 9.0g/dL . Inadequate hepatic function define AST/ALT &gt; 3x upper limit normal ( ULN ) , Total bilirubin &gt; 2x ULN , Alkaline phosphatase &gt; 3x ULN . Symptomatic brain metastasis require radiation therapy escalate dos steroid . Patients clinically stable brain metastasis leptomeningeal disease ( previously treat untreated ) eligible . Patients expansion cohort A must least one untreated CNS lesion Women breastfeed pregnant . Any evidence clinically active interstitial lung disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Erlotinib</keyword>
	<keyword>12-278</keyword>
	<keyword>CNS involvement</keyword>
</DOC>